Cho MH, Ahn YH, Lim SH, et al. - Because hyperuricemia is a common finding in typical hemolytic uremic syndrome (HUS) that may contribute to kidney damage, researchers ascertained if aggressive management of hyperuricemia with rasburicase could improve outcomes in acute kidney injury (AKI) patients with typical HUS. Between 2005 and 2017, medical records of children with typical HUS admitted to a tertiary center were analyzed retrospectively. Clinical outcomes of hospitalization and 1-year post-discharge were compared between those with rasburicase treatment (n = 13) and those without (controls, n = 29). Children with typical HUS treated with rasburicase at 1-year post-discharge had shorter hospital stays and fewer long-term sequelae than those not treated with rasburicase. Such outcomes promote the use of rasburicase in pediatric patients with typical HUS-associated AKI to prevent CKD.